AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05613751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Three text messages that are sent four weeks apart reminding to obtain the vaccines
Study NCT05606588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful sensorimotor training
Description: For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue.
Study NCT04981574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching on low back area and thoracic thrust manipulation
Description: 1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times.
Study NCT05868772 — intervention group
Intervention type: DEVICE
Intervention: Active Sentry Handpiece
Description: With low IOP settings
Study NCT05868772 — intervention group
Intervention type: DEVICE
Intervention: Ozil Handpiece
Description: With high IOP settings.
Study NCT04750850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic core stability exercises
Description: exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
Study NCT04750850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual routine as walking and activities of daily living.
Study NCT05141149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
Study NCT05141149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
Study NCT04960644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
Study NCT04960644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
Study NCT00240851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen extended release
Study NCT04995172 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo mobile CT-assisted bronchoscopy
Study NCT04995172 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Patients' medical records are reviewed
Study NCT04995172 — intervention group
Intervention type: PROCEDURE
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo radial probe EBUS
Study NCT00859001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM+R
Description: Fludarabine-Mitoxantrone-Rituximab
Study NCT00859001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (Ibritumomab Tiuxetan)
Study NCT05357326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate 0.01% Eye Drop
Description: use one drop into subconjunctiva
Study NCT05357326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Description: wear orthokeratology at night while sleeping
Study NCT05357326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 0.04% Eye Drop
Description: use one drop into subconjunctiva
Study NCT04848454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab with vinorelbine and cisplatin
Description: Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
Study NCT05160558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm
Study NCT05160558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm
Study NCT04885101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISWT Group
Description: The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
Study NCT04885101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NARFT Group
Description: The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
Study NCT04885101 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
Study NCT06310382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH55
Description: GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
Study NCT05936034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients suffering from chemotherapy-induced ototoxicity
Description: At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire.
Study NCT05936034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids
Description: At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire.
Study NCT05196360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-10181
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study NCT05518266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided Parasternal block
Description: Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
Study NCT05518266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon-delivered parasternal block
Description: Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
Study NCT06415266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire (QLQ)
Description: Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
Study NCT06415266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaire (QLQ)
Description: Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
Study NCT06415266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Description: The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
Study NCT06415266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Satisfaction survey
Description: The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
Study NCT06415266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of patient needs in the field of oncosexology
Description: Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
Study NCT05695092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
Study NCT05695092 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: control group will not receive any intervention
Study NCT05707143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home based stabilization exercises
Description: 3 times per day with 10 repetitions and holding time will be 5-10 sec
Study NCT04816487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide or Glutathione
Description: Patient will receive either Glutathione or Potassium iodide
Study NCT04816487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Iodide or Glutathione
Description: Patient will receive either Glutathione or Potassium iodide
Study NCT06131892 — intervention group
Intervention type: OTHER
Intervention: Defibrillation
Description: Defibrillation
Study NCT06111040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement
Description: The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
Study NCT05861063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
Study NCT05861063 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional CO2 laser
Description: All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
Study NCT05861063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
Study NCT04959136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory Monitoring Solution
Description: Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
Study NCT06436144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
Study NCT05707143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kegel exercises
Description: 3 times per day with 10 repetitions and holding time will be 5-10 sec
Study NCT06048406 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Health education
Description: The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
Study NCT05602610 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06021678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX103 injection
Description: Administered as specified in the treatment arm.
Study NCT05518448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone - beta-hydroxybutyrate (β-OHB)
Description: Ketone - beta-hydroxybutyrate (β-OHB)
Study NCT05518448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ketone - beta-hydroxybutyrate (β-OHB)
Description: Ketone - beta-hydroxybutyrate (β-OHB)
Study NCT05342207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy
Description: A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
Study NCT05473819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Local Anesthesia
Description: Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present.
Study NCT05473819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Unbuffered Local Anesthesia
Description: The control group will receive the unbuffered conventional anaesthetic solution
Study NCT04606927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natriuresis
Description: Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
Study NCT05717582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apalutamide
Description: Patients receive apalutamide 240mg,qd,po.
Study NCT05717582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Patients receive systemic ADT.
Study NCT05717582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive radical prostatectomy with/without pelvic lymph node dissection
Description: Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
Study NCT05717582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed therapy with radiation
Description: Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
Study NCT04844125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209
Study NCT04844125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1209 Placebo
Description: SHR-1209 Placebo
Study NCT06091904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Study NCT06326632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant-load Aerobic Exercise
Description: The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
Study NCT06326632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Aerobic exercise
Description: The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.